These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37755071)

  • 1. DNL151, DNL201, and BIIB094: experimental agents for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Investig Drugs; 2023; 32(9):787-792. PubMed ID: 37755071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.
    Cao R; Chen C; Wen J; Zhao W; Zhang C; Sun L; Yuan L; Wu C; Shan L; Xi M; Sun H
    Bioorg Chem; 2023 Dec; 141():106906. PubMed ID: 37837728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease.
    Jennings D; Huntwork-Rodriguez S; Henry AG; Sasaki JC; Meisner R; Diaz D; Solanoy H; Wang X; Negrou E; Bondar VV; Ghosh R; Maloney MT; Propson NE; Zhu Y; Maciuca RD; Harris L; Kay A; LeWitt P; King TA; Kern D; Ellenbogen A; Goodman I; Siderowf A; Aldred J; Omidvar O; Masoud ST; Davis SS; Arguello A; Estrada AA; de Vicente J; Sweeney ZK; Astarita G; Borin MT; Wong BK; Wong H; Nguyen H; Scearce-Levie K; Ho C; Troyer MD
    Sci Transl Med; 2022 Jun; 14(648):eabj2658. PubMed ID: 35675433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients.
    Atashrazm F; Hammond D; Perera G; Bolliger MF; Matar E; Halliday GM; Schüle B; Lewis SJG; Nichols RJ; Dzamko N
    Mov Disord; 2019 Mar; 34(3):406-415. PubMed ID: 30597610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-present).
    Ding X; Ren F
    Expert Opin Ther Pat; 2020 Apr; 30(4):275-286. PubMed ID: 32049564
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
    Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
    Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuron-autonomous susceptibility to induced synuclein aggregation is exacerbated by endogenous
    MacIsaac S; Quevedo Melo T; Zhang Y; Volta M; Farrer MJ; Milnerwood AJ
    Brain Commun; 2020; 2(1):fcz052. PubMed ID: 32510053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of leucine-rich repeat kinase 2 (LRRK2): progress and promise for the treatment of Parkinson's disease.
    Gilligan PJ
    Curr Top Med Chem; 2015; 15(10):927-38. PubMed ID: 25832719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play.
    Azeggagh S; Berwick DC
    Br J Pharmacol; 2022 Apr; 179(8):1478-1495. PubMed ID: 34050929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications.
    Yue Z; Lachenmayer ML
    Mov Disord; 2011 Jul; 26(8):1386-97. PubMed ID: 21538530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LRRK2 levels in immune cells are increased in Parkinson's disease.
    Cook DA; Kannarkat GT; Cintron AF; Butkovich LM; Fraser KB; Chang J; Grigoryan N; Factor SA; West AB; Boss JM; Tansey MG
    NPJ Parkinsons Dis; 2017; 3():11. PubMed ID: 28649611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the Role of SNCA, LRRK2, and GBA in Chinese Patients With Early-Onset Parkinson's Disease.
    Chen Y; Gu X; Ou R; Zhang L; Hou Y; Liu K; Cao B; Wei Q; Li C; Song W; Zhao B; Wu Y; Cheng J; Shang H
    Mov Disord; 2020 Nov; 35(11):2046-2055. PubMed ID: 32677286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
    Kethiri RR; Bakthavatchalam R
    Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leucine-rich repeat kinase 2-linked Parkinson's disease: clinical and molecular findings.
    Kumari U; Tan EK
    J Mov Disord; 2010 Oct; 3(2):25-31. PubMed ID: 24868377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Update on the Development of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors: A Promising Target for the Treatment of Parkinson's Disease.
    Patel A; Patel S; Mehta M; Patel Y; Langaliya D; Bhalodiya S; Bambharoliya T
    Med Chem; 2022; 18(7):757-771. PubMed ID: 35168510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease: leucine-rich repeat kinase 2 and autophagy, intimate enemies.
    Bravo-San Pedro JM; Gómez-Sánchez R; Pizarro-Estrella E; Niso-Santano M; González-Polo RA; Fuentes Rodríguez JM
    Parkinsons Dis; 2012; 2012():151039. PubMed ID: 22970411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
    Monfrini E; Di Fonzo A
    Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
    Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
    Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leucine-Rich Repeat Kinase 2 in Parkinson's Disease: Updated from Pathogenesis to Potential Therapeutic Target.
    Chen J; Chen Y; Pu J
    Eur Neurol; 2018; 79(5-6):256-265. PubMed ID: 29705795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson's disease.
    Kluss JH; Lewis PA; Greggio E
    Expert Opin Ther Targets; 2022 Jun; 26(6):537-546. PubMed ID: 35642531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.